Nonetheless, AZD1775 at 30 mg/kg in both monotherapy and combined treatment groups resulted in a decrease in phosphorylation of CDC2 (CDK1) at Tyr15 indicating effective inhibition of WEE1 in the AT3 tumours at this reduced dose (Supplementary Fig. 2d). Here, WEE1 is linked to neoplasm.